MYRIAD GENETICS INC
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
MYGN$5.67-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations for the and (unaudited)
Condensed Consolidated Statements of Operations (unaudited)
(in millions, except per share amounts)
| Three months endedMarch 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue | $195.9 | $202.2 |
| Cost of revenue | 61.7 | 64.6 |
| Gross profit | 134.2 | 137.6 |
| Costs and expenses: | ||
| Research and development expense | 27.5 | 24.9 |
| Sales and marketing expense | 69.2 | 69.4 |
| General and administrative expense | 66.5 | 71.2 |
| Total operating expenses | 163.2 | 165.5 |
| Operating loss | (29.0) | (27.9) |
| Other income (expense): | ||
| Interest income | 0.3 | 0.6 |
| Interest expense | (0.8) | (0.5) |
| Other | 0.1 | 1.9 |
| Total other income (expense), net | (0.4) | 2.0 |
| Loss before income tax | (29.4) | (25.9) |
| Income tax (benefit) expense | (29.3) | 0.1 |
| Net loss | $(0.1) | $(26.0) |
| Net loss per share: | ||
| Basic and Diluted | $— | $(0.29) |
| Weighted average shares outstanding: | ||
| Basic and Diluted | 91.4 | 89.9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.